Hims & Hers Health (NYSE:HIMS) Trading 5.8% Higher - Here's What Happened

Key Points

• Hims & Hers Health's stock price rose 5.8% to $57.96, though trading volume was down by 28% compared to the average session.
• Recent analyst ratings reflect a consensus of "Reduce", with estimates setting an average target price of $38.92.
• The company reported a net margin of 9.63% and a revenue increase of 72.6% year-over-year for the last quarter, despite missing earnings estimates.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price traded up 5.8% on Tuesday . The company traded as high as $57.93 and last traded at $57.96. 23,439,635 shares traded hands during mid-day trading, a decline of 28% from the average session volume of 32,681,494 shares. The stock had previously closed at $54.76.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Zacks Research lowered shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Hims & Hers Health in a research report on Saturday, September 27th. Finally, Truist Financial dropped their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Stock Up 5.6%

The firm has a market capitalization of $13.07 billion, a PE ratio of 72.29, a P/E/G ratio of 3.55 and a beta of 2.25. The firm's 50 day moving average price is $51.39 and its two-hundred day moving average price is $47.49. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, insider Michael Chi sold 2,100 shares of the company's stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $56.52, for a total value of $118,692.00. Following the sale, the insider directly owned 291,439 shares of the company's stock, valued at $16,472,132.28. This represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Irene Becklund sold 8,410 shares of the company's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $424,705.00. Following the completion of the sale, the insider directly owned 1,418 shares in the company, valued at $71,609. This represents a 85.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,611,146 shares of company stock valued at $83,026,206 over the last ninety days. 17.71% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of the business. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 15.7% during the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock valued at $49,000 after buying an additional 227 shares during the period. GAMMA Investing LLC increased its stake in shares of Hims & Hers Health by 6.1% during the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company's stock valued at $232,000 after acquiring an additional 236 shares during the period. Bessemer Group Inc. increased its stake in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after acquiring an additional 312 shares during the period. True Vision MN LLC raised its holdings in Hims & Hers Health by 3.6% during the second quarter. True Vision MN LLC now owns 9,376 shares of the company's stock worth $467,000 after purchasing an additional 328 shares in the last quarter. Finally, Allworth Financial LP lifted its position in Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after purchasing an additional 334 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.